Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,773 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,496 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,526)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06404164 | Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection | recruiting | N/A | 3,000 | Guangdong Provincial People's HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06399926 | Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir | recruiting | — | 64 | Xiangya Hospital of Central South UniversityOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT06300177 | D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure | recruiting | Phase 3 | 522 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06387017 | Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway(BIOCEPTION) | recruiting | N/A | 750 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06369181 | Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC | recruiting | — | 50 | Fudan UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06169956 | An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany(NENI) | recruiting | — | 400 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 18, 2024 | clinicaltrials |
| NCT02889666 | A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer(CCODG-NSCLC) | recruiting | Phase 1 | 500 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363734 | Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial | recruiting | Phase 2 | 32 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06361784 | Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS)(LM) | recruiting | — | 150 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05704920 | Integrating Artificial Intelligence Into Lung Cancer Screening.(DACAPO) | recruiting | N/A | 2,722 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06361589 | Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients | recruiting | — | 200 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06360627 | Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT | recruiting | N/A | 100 | University of ZurichOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06223711 | Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC | recruiting | Phase 2 | 43 | Universität des SaarlandesOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT06339255 | Italian Observational Study on CAR-T Therapy for Lymphoma(CART-SIE) | recruiting | — | 5,300 | Paolo CorradiniOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06301945 | Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors(INTHYM) | recruiting | — | 1,020 | Erasmus Medical CenterOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06329908 | DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs | recruiting | Early Phase 1 | 20 | Zhen-Yu DingOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06327594 | Assessment System of Sarcopenia in Lung Cancer Patients | recruiting | — | 1,500 | West China HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04733430 | LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice(LALUCA) | recruiting | — | 500 | Karl Landsteiner Institute for Lung Research and Pneumological OncologyOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06225804 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer | recruiting | Phase 1 | 164 | Abbisko Therapeutics Co, LtdINDUSTRY | 2 | Mar 18, 2024 | clinicaltrials |
| NCT06020430 | Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy | recruiting | N/A | 134 | Hubei Cancer HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06032052 | Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients | recruiting | Phase 2 | 49 | Hubei Cancer HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06037733 | Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy | recruiting | N/A | 134 | Hubei Cancer HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06128837 | Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | recruiting | Phase 3 | 686 | Luye Pharma Group Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA) | recruiting | Phase 1 | 50 | Lebanese UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06053099 | A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)(ROSIE) | recruiting | N/A | 300 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT05085028 | A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)(REFINE-Lung) | recruiting | Phase 3 | 1,750 | Imperial College LondonOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06286150 | Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery | recruiting | N/A | 20 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT05332925 | Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC(TUMORIN) | recruiting | — | 25 | Jun Zhang, MD, PhDOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05377658 | AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer | recruiting | Phase 2 | 43 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05965024 | Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer | recruiting | — | 377 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06255197 | Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers | recruiting | — | 60,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06262386 | Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial | recruiting | N/A | 358 | Chang Gung Memorial HospitalOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06241807 | Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC | recruiting | Phase 2 | 30 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06247605 | A Phase IIII Study of AL8326 in Small Cell Lung Cancer | recruiting | Phase 3 | 243 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06243003 | WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases | recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05382728 | Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) | recruiting | Phase 3 | 680 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06229340 | Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations(NТО-RAS) | recruiting | Phase 2 | 20 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT06007261 | Validation of Rapid On-site Diagnostics in Early Stage Lung Cancer Sampling With a Higher Harmonic Generation Microscope(VALIDIAG) | recruiting | — | 250 | Radboud University Medical CenterOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06216782 | Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study | recruiting | — | 2,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT05011487 | Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC(NOCE01) | recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06198868 | MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC | recruiting | — | 60 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04235114 | Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET) | recruiting | Phase 1 / Phase 2 | 14 | University of SaskatchewanOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04459065 | Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery | recruiting | Phase 1 / Phase 2 | 36 | University of SaskatchewanOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04938804 | Non-risk Based Lang Cancer Screening With a One-off LDCT | recruiting | N/A | 11,000 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06188650 | The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study | recruiting | N/A | 30 | Ningbo Medical Center Lihuili HospitalOTHER_GOV | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06188676 | Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL | recruiting | Phase 3 | 100 | National Research Center for Hematology, RussiaNETWORK | 1 | Jan 3, 2024 | clinicaltrials |
| NCT05349552 | Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites | recruiting | — | 120 | Peking University Third HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06177925 | A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | recruiting | Phase 2 | 62 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
Data updated 22 days agoSource updated May 8, 2024source: clinicaltrials